MedTrace Logo

A Phase I Study of a New Tuberculosis (TB) Vaccine, MVA85A, in Healthy Volunteers With HIV

NCT00731471 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 24

Last updated 2011-03-28

No results posted yet for this study

Summary

This is an open Phase I study of a candidate TB vaccine, MVA85A, in healthy subjects who are infected with HIV. It is designed to study the safety and immunogenicity of the vaccine.

Conditions

Interventions

BIOLOGICAL

MVA85A

Modified vaccinia virus Ankara expressing antigen 85A from Mycobacterium tuberculosis. Both arms will receive two vaccinations six months apart.

Sponsors & Collaborators

  • Centre Hospitalier Universitaire Le Dantec, Dakar, Senegal

    collaborator UNKNOWN

  • University of Oxford

    lead OTHER

Principal Investigators

  • Helen McShane · University of Oxford

  • Souleymane Mboup · Centre Hospitalier Universitaire Le Dantec

Study Design

Allocation
NON_RANDOMIZED
Purpose
PREVENTION
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
50 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-08-31
Primary Completion
2011-01-31
Completion
2011-01-31

Countries

  • Senegal

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00731471 on ClinicalTrials.gov